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Abstract
The TAR RNA of HIV was engineered as an siRNA delivery vehicle to develop a combinatorial therapeutic approach.
The TAR backbone was found to be a versatile backbone for expressing siRNAs. Upon expression in human cells,
pronounced and specific inhibition of reporter gene expression was observed with TARmiR. The resulting TARmiR
construct retained its ability to bind Tat and mediate RNAi. TARmiR was able to inhibit HIV gene expression as a
TAR decoy and by RNA interference when challenged with infectious proviral DNA. The implications of this dual
function therapeutic would be discussed.
Background
S i n c ei t sd i s c o v e r yi nt h ee i g h ties, significant progress
has been made in attempts to control HIV. Several stra-
tegies have been adopted including the use of small
molecule drugs to inhibit various stages in the viral life
cycle collectively called a HAART regimen. Unfortu-
nately, nearly all HIV-infected individuals on HAART
will need to maintain their medications for the entirety
of their lives, resulting in considerable expense and
sometimes the toxic side effects of these drugs. Accord-
ing to recent reports, in the age of HAART the majority
of emergency room visits by HIV-infected individuals
has shifted from opportunistic infections to treatments
for antiretroviral drug-related toxicities. Thus there is a
clear need to develop alternative therapies to treating
HIV infections. Alternative approaches to inhibit HIV
have explored the use of a genetic type of therapy where
HIV susceptible T-cells or stem cells that are precursors
of HIV susceptible cells have been engineered to express
anti-HIV molecules. These include oligonucleotide-
based antivirals like siRNA, ribozymes, suicide genes or
transdominant negative mutant proteins of HIV. Many
of these approaches have shown promise at restricting
viral replication. Some genetic therapy approaches have
also progressed to clinical trials. However a serious lim-
itation with designing anti-HIV therapies is the ability of
the virus to evolve and become resistant to any one
therapeutic approach. This is due to the low fidelity of
the HIV reverse transcriptase. Hence it is essential to
develop intervention strategies that can significantly
restrict the ability of the virus to become resistant to it.
One way this can be achieved is by using an approach
where two or more inhibitors are used in combination
such that if the virus manages to become resistant to
one, it is inhibited by another. Another escape proof
strategy is to interfere with normal viral RNA protein
interactions that are critical in HIV life cycle namely the
Tat-TAR interaction or the Rev RRE interaction. Indeed
several studies including ours have explored the use of
TAR or RRE decoys [1-3] or the use of transdominant
negative mutants of rev[4,5]. We have earlier reported a
combinatorial approach where an anti-HIV siRNA is co-
expressed along with Rev M10, a transdominant nega-
tive mutant of HIV rev to effect a pronounced inhibition
of HIV, concomitantly suppressing the emergence of
viral mutants in T-cell lines[6].
RNAi mediated gene silencing can be achieved by
either transfecting dsRNA [7,8] or plasmids expressing
the siRNA either as sense and antisense strand or as a
hairpin[9,10]. The proteins involved in RNAi are evolu-
tionarily conserved and play a role in silencing of devel-
opmentally important genes. siRNAs exploit the an
endogenous miRNA pathway to mediate RNAi. Micro-
RNAs (miRNAs) are an important class of small, non-
coding, regulatory RNAs found to be involved in
regulating a wide variety of important cellular processes
by the sequence-specific inhibition of gene expression.
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cellular processes, including differentiation, develop-
ment, and metabolism (For review see [11-13].
Some studies have also reported that siRNAs
expressed from a microRNA backbone could efficiently
inhibit cognate gene expression[14]. Cloning of small
RNAs from viruses demonstrated the presence of micro-
RNAs encoded by viruses [15-17]. miRNAs have several
characteristics that make them an attractive option for
viruses to utilize in the regulation of gene expression.
miRNAs could be envisioned to function in viral patho-
genesis in several ways, including the regulation of viral
gene expression by host miRNAs, the regulation of viral
gene expression by virus encoded miRNAs, and the reg-
ulation of host genes by virus encoded miRNAs.
Recently Ouellette et. al. [18] reported the processing
and release of functional microRNAs from the HIV
transactivation response element (TAR). They further
went on to report that the processed microRNA can
mediate RNA interference.
TAR element is a structured RNA located at the 5’
end of all transcripts derived from HIV-1[19,20]. It is a
master switch that turns ON HIV replication. By inter-
fering with the Tat-TAR interaction one can have an
amplifying effect whereby the viral transcription never
takes off. Michienzi et. al. have reported a robust inhibi-
tion of viral replication by expressing a nucleolar loca-
lized TAR decoy[3].
In this study we report the expression of an anti-HIV
siRNA from the TAR RNA backbone. We further go on
to demonstrate that the anti-HIV Tar-miRNA construct
can function as dual-function therapeutic serving as a
TAR decoy as well as an siRNA delivery vehicle. This
dual function anti-HIV TARmiR causes potent inhibi-
tion of HIV gene expression when delivered directly or
expressed in HIV infected cells. The potential advan-
tages and applications of this system would be
discussed.
Results
Anti-HIV TARmiR inhibits cognate gene expression
To determine if an anti-HIV siRNA can be expressed in
the context of the HIV TAR element, siRNA sequence
corresponding to the earlier reported site II of HIV Rev
was inserted in place of the cognate TAR miRNA
sequence. It is also essential to retain the proper folding
of the TAR bulge to ensure that the TARmiR can also
function as a TAR decoy. Several configurations of TAR
were designed and folded in silico to determine if the
TAR stem folds correctly. In one configuration, a perfect
stem corresponding to the sequence of the siRNA was
incorporated in TARmiR. The modification alters the
TAT binding region of TAR and has been reported to
inhibit TAT binding (TARmiR- perfect stem) [21]. In
order to retain the correct folding of TAR, two config-
urations were selected, one in which both the single-
nucleotide bulges are retained as in the wild type TAR
and another in which the distal bulge near the Tat bind-
ing region is retained (Figure 1A). The anti- rev siRNA
target site corresponding to our previously reported site
II was cloned in the siCHECK plasmid (Promega). The
TAR microRNAs were in vitro transcribed using the T7
transcription kit from Promega. Earlier reports have
indicated that T7 transcribed RNA can activate a non-
specific innate immune response [22]. To prevent this
and to ensure that inhibition of HIV gene expression is
due to the siRNA effect, the TAR miRNA was treated
with Calf intestinal alkaline phosphatase (CIAP) to
remove the initiating triphosphate. The CIP treated
anti-site II rev TARmiR were then co-transfected with
the siCHECK plasmid carrying the rev target in the 3’
UTR of Renilla luciferase. 48 hours post-transfection the
cells were harvested and the luciferase activity measured
according to the manufacturer’s instructions. siCHECK
transfected with a similarly transcribed anti-site II rev
shRNA was used for comparison. As seen in figure 1B,
~80% inhibition of the target is observed with the in
vitro transcribed shRNA. A comparable inhibition is
observed with the configuration where both the single-
nucleotide bulges are retained. The configuration where
the proximal bulge is removed showed a dramatic inhi-
bition three fold better than the in vitro transcribed
shRNA suggesting that the siRNA expressed from this
configuration was much more potent than expressing it
from a hairpin. This could be expected since TAR is
naturally processed into microRNA and hence is a nat-
ural substrate for DICER. TAR is also known to recruit
the TAR RNA binding protein (TRBP), which is an
important component of the RNAi machinery. In order
to determine if the presence of Tat binding region of
TAR contributes to RNAi in any way, a perfect stem
with the TAR sequence minus the bulges, TARmiR-per-
fect stem, was separately tested as a control. The TAR-
miR-perfect stem construct inhibited target gene
expression in siCheck Assays with an efficiency compar-
able to that observed with anti-Rev shRNA (Additional
file 1) To determine the versatility of the TAR RNA
backbone for expressing siRNA, we replaced the Rev
s i t eI Iw i t has i t ef o rT G F - b gene. This anti-TGF-b
TARmiR was similarly transcribed and co-transfected
with siCheck plasmid carrying the TGF-b target site. As
seen in figure 1C, ~60% inhibition of target gene expres-
sion is observed. The inhibition by both, the anti-site II
rev and anti-TGF-b TARmiR RNA was specific to its
cognate siCHECK targets. No inhibition was observed
by anti-TGF-b TARmiR for the HIV rev target (Addi-
tional file 2; 2A). Neither of the two anti-HIV TARmiR
configurations nor the anti-rev shRNA demonstrated
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Page 2 of 9Figure 1 Inhibition of target gene expression by siRNAs expressed from the TAR microRNA backbone. (A) siRNA sequence targeting the
earlier reported site II of HIV rev was folded in silico and the configurations that retained the correct Tat binding region were selected for
further studies. Configurations I & II have the lower single nucleotide bulge removed or both the bulges retained respectively. Configuration III is
the anti-site II Rev shRNA with the 9 nt loop reported earlier by us[28]. Arrows indicate single nucleotide bulge (B) Target site corresponding to
the site II of HIV rev is cloned in the 3’ untranslated region of the renilla luciferase ORF in the siCHECK vector. The three configurations of siRNA
were invitro transcribed and treated with Calf intestinal alkaline phosphatase. The CIP treated RNA were then cotransfected with the psiCHECK
plasmid having the Rev Target site. Dramatic inhibition of reporter gene expression is observed with all three configurations. The configuration
where the lower bulge is removed is three-fold more potent than even the anti-Rev shRNA. (C) An siRNA targeting TGF-b is expressed in a
similar fashion from the TAR miRNA backbone and co-transfected with siCHECK plasmid having the TGF-b target site. ~70% inhibition is
observed with this construct suggesting that the TAR miRNA is a versatile backbone for expressing siRNA. All siCHECK assays are a mean of three
experiments. CFI and CFII = Configuration I and Configuration II.
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cloned as target (Additional file 2; 2B). Thus the TAR
b a c k b o n es e r v e sa sav e r s a t i l ee x p r e s s i o nv e h i c l ef o r
siRNA.
Anti-HIV TARmiR functions via the siRNA pathway
Since the siCheck system involves cloning the target in
the 3’ UTR of the Renilla luciferase, the system is ideal
for detecting both an siRNA and an miRNA effect.
However it is quite possible that the siRNA sized frag-
ment released from TARmiR could have a potent
miRNA effect that is readily detectable by siCHECK
but may not work if the target is within the open read-
ing frame (as an siRNA). To test whether the TARmiR
can inhibit HIV rev as an siRNA, CMV RevEGFP plas-
mid that encodes a full-length functional Rev fused to
the EGFP sequence was co-transfected with the distal
single-nucleotide bulge containing configuration of
TARmiR. As seen in figure 2, a potent inhibition of
RevEGFP expression is observed in presence of the
TARmiR. Cells receiving irrelevant siRNA did not
show any inhibition.
Anti-site II rev TARmiR can bind Tat
To determine if either of the TARmiR configurations bind
Tat and can potentially serve in the dual role of a TAR
decoy and an siRNA vehicle, both the configurations were
end-labeled and allowed to bind a previously reported Tat
derived peptide corresponding to the region of Tat that
binds TAR [23]. To determine if the binding is TAT speci-
fic, the influenza HA2 fusion peptide was allowed to bind
TARmiR configuration I. As seen in figure 3, a mobility
shift is observed with both the configurations while the
HA-2 peptide does not show any binding. This validates
our in silico folding data demonstrating that both the con-
figurations fold correctly and retain their TAT binding
abilities and can potentially function as a TAR decoy as
well as function in RNAi.
Figure 2 anti- rev TARmiR configuration I can function as siRNA in RNA interference: HEK 293 cells were co-transfected with CMV
RevEGFP and the anti-HIV TARmiR configuration I. Potent inhibition of EGFP expression is observed in these cells suggesting that the siRNA
sized fragments released from the TARmiR backbone can demonstrate RNAi even when the target site is present within the ORF.
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expressed from a U6 promoter
To determine if the TARmiR construct can serve as a dual
function therapeutic when expressed in cells, we used a
PCR based approach for rapid synthesis of U6 promoter-
TARmiR constructs as reported earlier by our laboratory
[24]. Both the Rev site II containing and TGF-b containing
TARmiR were similarly generated (Fig 4A). HEK 293 cells
were co-transfected with the infectious proviral DNA,
pNL4-3 and U6 promoter PCR cassettes containing either
irrelevant shRNA, anti-Rev containing TARmiR, anti-
TGF-b containing TARmiR or Rev site II shRNA. Culture
supernatants were collected on day3 and the p24 levels in
the supernatant were determined using a p24 ELISA kit.
As seen in figure 4B, inhibition is observed with all the U6
constructs with maximal inhibition observed with the
anti-HIV shRNA and anti-HIV TARmiR. Some inhibition
is also observed with the anti-TGF-b TARmiR. This inhi-
bition could be attributed to the presence of the TAR
bulge that would serve as a TAR decoy and hence seques-
ter Tat thereby down-regulating transcription from the
LTR of pNL4-3. This demonstrates that expressing anti-
HIV siRNA from the TAR backbone can have a dual
impact on HIV replication in that the TAR bulge could
serve as a TAR decoy whereas the processed siRNA can
inhibit HIV via RNA interference.
Figure 3 Gel mobility shift assay: anti-HIV TARmiR configuration I or II was transcribed in vitro, end labeled and was allowed to bind
to a peptide corresponding to the arginine rich region of Tat that is responsible for binding TAR [23]. A mobility shift (arrow) clearly
demonstrates Tat peptide binding to the TARmiR. As a control the fusion peptide HA-2 of influenza was used to bind the TARmiR configuration
I. No shift in mobility is observed with HA2.
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Here we show that siRNA expressed from HIV TAR
backbone successfully inhibits HIV by mediating RNAi
as well as serving as a TAR decoy. Several configura-
tions of TARmiR were designed and folded in-silico to
determine if placing the anti-HIV rev siRNA within the
TAR backbone alters the correct TAR folding. It is
essential to preserve the correct structure of the TAR
bulge to facilitate TAT binding for the TARmiR to
serve as a TAR decoy. It was determined that replacing
both the single nucleotide bulges in the TAR stem loop
with a perfect stem alters the structure of the TAR
bulge (data not shown). Two configurations of TAR
were tested which both retained the structure of the
TAR loop, one in which both bulges were retained as in
the original HIV TAR and the other where only the dis-
tal bulge is retained. Both these configurations demon-
strated pronounced inhibition of reporter gene
expression. The distal single nucleotide bulge-containing
configuration was three times more potent than the
configuration with both the bulges as well as a conven-
tional shRNA targeting the same site. We were able to
demonstrate target knockdown both, when the target is
in the 3’ UTR of the reporter gene as well as when the
Figure 4 Inhibition of HIV gene expression by TARmiR constructs. (A) Generation of U6-TARmiR PCR constructs. An PCR expression cassette
with the U6 promoter driving the expression of anti-rev TARmiR, anti-TGF-b TARmiR or anti-Rev shRNA is generated as described earlier by us
[24]. (B) HEK 293 cells are co-transfected with infectious proviral DNA pNL4-3 and U6anti-Rev TARmiR configuration I, U6 anti-TGF-b TARmiR or
U6anti-Rev shRNA. Pronounced inhibition is observed with both, the anti-Rev shRNA and anti-Rev TARmiR. Inhibition is also observed with anti-
TGF-b TARmiR. This could be due to the presence of an intact TAT binding bulge which serves in the capacity of a TAR decoy.
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RevEGFP expression. Both the configurations retained
their ability to bind HIV tat as demonstrated by gel
mobility shift analysis. The binding was specific since an
unrelated peptide of influenza virus failed to bind this
configuration. The engineered TAR retained its ability
to bind HIV tat and demonstrated a TAR decoy effect
when an unrelated siRNA was expressed from its back-
bone in co-transfection experiments with infectious HIV
proviral DNA.
Several reports including one from our laboratory
have demonstrated efficient inhibition of HIV gene
expression using TAR decoys[3]. The Tat-TAR interac-
tion is very critical for HIV and serves as a master
switch that turns ON gene expression. While the HIV
LTR is very efficient at transcription initiation, RNA
polymerase II is non-processive. It transcribes TAR
and pauses at the base of the TAR loop. HIV TAT
binds TAR and recruits the transcription factor PTEF-
b kinase, which is a heterodimer of CDK-9 and cyclin
T1. CDK9 phosphorylates the C-terminal domain of
Pol II and makes it processive allowing the transcrip-
tion to proceed. However binding of NF-kb subunits in
response to cellular events or signal transduction can
also result in efficient initiation and elongation of tran-
scription. Of note the p65 subunit of NF-kb can make
the Pol II elongation competent. Thus allowing a lower
level of transcription to proceed even in absence of
Tat.
Expressing an siRNA from the backbone of TAR can
provide the second tier of inhibition and target tran-
scription that is TAT independent or, in case the TAR
decoy is overwhelmed by excessive transcription from
the HIV LTR. Moreover such a construct would pro-
vide a single RNA molecule that can target HIV in two
different ways. The ability to do so can simplify issues
with expression of these as a transgene as in case of
gene therapy or delivery of this RNA molecule to HIV
infected/susceptible cells when coupled to either T-cell
specific monoclonal antibodies[25] or HIV gp160 apta-
mers [26]. Indeed when combined with anti-HIV apta-
mers as demonstrated by Zhou et. al. [26] one can
create a single RNA molecule that inhibits HIV in
three distinct ways where the gp120 aptamer can neu-
tralize the free virus or bind to infected cell surface
and block cell-cell fusion, the TAR bulge can serve as
a TAR decoy and the siRNA can target the HIV tran-
script. In our earlier work we have demonstrated that
targeting HIV with shRNA alone can allow selection of
mutants that are resistant to the shRNA[6]. Such
mutants are observed within 40 days of culturing the
virus with cells stably expressing these shRNA. How-
ever when a combinatorial approach was used where
the siRNA was co-expressed with the transdominant
negative mutant of rev (RevM10) we observed an addi-
tive effect and suppressed the emergence of resistant
mutants. It is quite possible that the TARmiR can
serve primarily as a TAR decoy and binding of tat to
TARmiR can block processing by DICER, meaning
that a molecule of TARmiR can either serve as a TAR
decoy or get processed to functional siRNA but not
both, we do not anticipate that to be a limitation of
this design since sufficient molecules of TARmiR
would be made available either by expression or deliv-
ery such that while some molecules would bind Tat
and serve as a TAR decoy others would still be avail-
able to get processed and mediate RNAi. Future work
would revolve around replacing the shRNA in our ear-
lier reported co-expression cassette with anti-site II
Rev TARmiR and co-expressed with revM10 to deliver
a triple blow to HIV from a single transgene cassette.
We anticipate a pronounced inhibition of HIV gene
expression using this cassette, which would also be
HIV inducible. Alternately these anti-HIV TARmiR
coupled to gp120 aptamers for delivering them directly
to HIV infected cells.
Materials and methods
Materials
Unless otherwise noted, all chemicals were purchased
from Sigma-Aldrich, all restriction enzymes were obtained
from New England Biolabs (NEB) and all cell culture
reagents were purchased from GIBCO (Invitrogen). The
Tat 48-57 peptide with the sequence YGRKKRRQRRRP
and HA-2 fusion peptide GLFEAIAGFIENGWEGMIDGK
were purchased from American peptide Company (Sunny-
vale CA).
Plasmids
Infectious proviral DNA clone pNL4-3 was obtained
from the NIH AIDS reagent and Reference program,
D i v i s i o no fA I D S ,N I A I D ,N I H .p s i C H E C K - 2P l a s m i d
was obtained from Promega corporation. To generate
siCHECK Plasmids having the rev site and TGF-b site,
DNA sequence corresponding to the siRNA sense
strand and its antisense strand with an Xho I site and
Not I site overhang was synthesized chemically,
annealed, digested with Xho I and Not I and ligated
into a similarly digested psiCHECK-2 plasmid.
Cell Culture
HEK 293 cells were purchased from American Type
Culture Collection and cultured in Dulbecco’sm o d i f i e d
eagle’s medium supplemented with 10% fetal bovine
serum in accordance with its respective data sheet. All
transfections were done using Lipofectamine 2000
reagent (Invitrogen) according to the manufacturer’s
instructions.
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All DNA oligonucleotides were purchased from Sigma.
The T7-TARmiR expression cassettes were generated as
described below.
Anti-Rev site II TARmiR configuration I:
Sense primer: Taatacgactcactata gggcctgtgcctctt
cagctaccacagatctgagcctggga
Antisense Primer: ttgggcctgtgcctcttcagctaccaagagagc
tcccaggctcagatctgtg
Anti-rev site II TARmiR configuration II:
Sense primer: Taatacgactcactata gggcctcgtgcctcttcag
ctaccacagatctgagcctggga
Antisense primer: ttgggcctgtgcctcttcagctaccaagaga
gctcccaggctcagatctgtg
Anti-TGF-b TARmiR configuration I
Sense primer: Taatacgactcactata gggcatgtcatcagctggg
aagacagatctgagccctggga
Antisense primer: ttgggcatgtcatcagctgggaagaagaga
gctcccagggctcagatctgtcttc
TAR-miR-perfect stem configuration:
Sense primer: Taatacgactcactata gggcctgtgcctcttca
gctaccttcatctgagcctggga
Antisense primer: ttgggcctgtgcctcttcagctaccaagagag
ctcccaggctcagatg
The sense and antisense primers were annealed as
described
Annealing Mix: 9 μl 100 mM Tris-HCl, pH 8.0 15 μl
50 mM MgCl2, 1 nmole sense primer, 1 nmole anti-
sense Oligo, total volume of 90 μl with MQ H2O
In a separate tube, 50 μl1 0 ×P C RB u f f e r( w i t h o u t
Mg), 4 μl 25 mM each dNTP, 2 μl Platinum Taq, 354 μl
MQ H2O, Divide into 5 × 82 μl reactions. All tubes
were heated to 93°C and then allowed to cool to room
temperature. Distribute 18 μl of the annealing reaction
into each of the Platinum Taq mixtures.
Extension reaction is carried out at 72°C for 10 min-
utes. The extension products are purified using Qiagen
PCR purification columns and the size confirmed by
running on agarose gel electrophoresis.
In vitro transcription
The primer extension products are then used for in
vitro transcription using the RiboMAX Large Scale RNA
Production System-T7 (Promega). For end-labeling reac-
tion, TARmiR RNA was 5’ labeled with [g-32P]ATP
(7000 Ci/mmol; MP Biomedicals) and T4 polynucleotide
kinase as previously described [27]
Dual luciferase assays
HEK 293 cells were transfected with 100 ngs of
siCHECK plasmid containing either the rev site II or
TGF-b target site and 10 pmoles of in vitro transcribed
either anti-site II rev or TGF-b TARmiR. 48 hours post-
transfection, cells were harvested for analysis. The
expression of Renilla luciferase and normalizing control
Firefly luciferase were detected using the Dual-luciferase
reporter assay system (Promega, Madison, WI), in accor-
dance with the manufacturer’s instructions. All samples
were transfected in triplicate, and the experiment was
performed a minimum of three times.
Gel retardation assay
TARmiR Configuration I and II were invitro transcribed
and labeled as mentioned above. For binding reaction
Peptide (TAT or HA2) and RNA were incubated
together for 10 min on ice in 10-ml binding reactions
containing 10 mM Tris-HCl (pH 7.5), 70 mM NaCl, 0.2
mM EDTA, and 5% glycerol. Peptide-RNA complexes
were resolved on 10% polyacrylamide, 0.5 × TBE gels
that had been prerun for 1 hr. Gels were electrophor-
esed at 200 V for 3 hr at 4°C, dried, and exposed to an
X-ray Film.
HIV challenges and p24 antigen assay
HEK 293 cells were co-transfected with the infectious
proviral DNA clone, pNL4-3 and the anti-site II rev
TARmiR, anti-TGF-b TARmiR or anti-site II rev
shRNA. 72 hours post-transfection, culture supernatants
were collected. The p24 antigen analyses were per-
formed using a Coulter HIV-1 p24 antigen assay (Beck-
man Coulter, Fullerton, CA) in accordance with the
manufacturer’s instructions.
Additional file 1: Inhibition of Target RNA expression with the
minus bulge control shows ~85% inhibition. The inhibition is
comparable to that observed with anti-Rev shRNA.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1743-422X-7-33-
S1.JPEG]
Additional file 2: HEK 293 cells were co-transfected with either of
the anti-HIV TARmiR configurations or anti-HIV shRNA and siCheck
plasmid having the TGF-b target site (A) or vice versa (B). Dual
Luciferase assay was performed as described in Materials and Methods.
As seen in the figure none of the TARmiR configurations or anti-Rev
shRNA demonstrated any inhibition of the non-cognate siCHECK.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1743-422X-7-33-
S2.JPEG]
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